文献速递脑血管病神经重症与神经感染

Otaplimastat在需tPA治疗的急性缺血性卒中患者中的安全性与有效性(SAFE-TPA):多中心、随机、双盲、安慰剂对照2期研究

Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
PubMed 文献 · Ann Neurol · 2019-11-29

本研究为2期多中心试验,评估Otaplimastat在接受rtPA的急性缺血性卒中患者中的安全性。第1阶段为11例开放标签安全性研究,第2阶段为69例随机双盲安慰剂对照研究。主要终点为第1天实质血肿(PH)发生率,结果显示PH发生率低且组间无差异,SAEs和死亡率无差异,Otaplimastat总体安全可行,功能有效性需进一步大型试验验证。

要点

  • Otaplimastat在rtPA后30分钟内静脉给药,80mg每日两次连续3天,安全性可行。
  • 第2阶段PH发生率:安慰剂0/22,40mg组0/22,80mg组1/21,组间无差异。
  • 3组SAEs(13%、17%、14%)和死亡(8.3%、4.2%、4.8%)无差异。

核心结论

  • 静脉Otaplimastat作为rtPA辅助治疗在急性缺血性卒中患者中可行且总体安全。

研究设计与样本

  • 2期、两部分、多中心试验,纳入19-80岁接受rtPA的卒中患者。
  • 第1阶段为单臂开放标签安全性研究,11例患者接受Otaplimastat 80mg每日两次共3天。
  • 第2阶段为随机双盲安慰剂对照研究,69例患者按1:1:1分配至Otaplimastat 40mg、80mg或安慰剂组。

主要发现

  • 第1阶段未发现安全问题。
  • 第2阶段第1天实质血肿(PH)发生率:安慰剂组0/22,40mg组0/22,80mg组1/21。
  • 3组严重不良事件(SAEs)发生率分别为13%、17%、14%,死亡率分别为8.3%、4.2%、4.8%,均无差异。
  • 3例不良事件(寒战、肌肉强直、肝毒性)被认为与Otaplimastat相关。

关键数值与推荐

  • 主要终点为第1天实质血肿(PH)发生。
  • 次要终点包括严重不良事件(SAEs)、死亡率和90天改良Rankin量表(mRS)分布。

临床怎么用

  • Otaplimastat可作为rtPA的辅助治疗,安全可行,但功能有效性需进一步大型试验验证。

局限性

  • 样本量较小(第2阶段69例),功能有效性结论有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receiving rtPA. METHODS: This was a phase 2, 2-part, multicenter trial in stroke patients (19-80 years old) receiving rtPA. Intravenous otaplimastat was administered <30 minutes after rtPA. Stage 1 was a single-arm, open-label safety study in 11 patients. Otaplimastat 80 mg was administered twice daily for 3 days. Stage 2 was a randomized, double-blind, placebo-controlled study involving 69 patients, assigned (1:1:1) to otaplimastat 40 mg, otaplimastat 80 mg, or a placebo. The primary endpoint was the occurrence of parenchymal hematoma (PH) on day 1. Secondary endpoints included serious adverse events (SAEs), mortality, and modified Rankin scale (mRS) distribution at 90 days (clinicaltrials.gov identifier: NCT02787278). RESULTS: No safety issues were encountered in stage 1. The incidence of PH during stage 2 was comparable: 0 of 22 with the placebo, 0 of 22 with otaplimastat 40 mg, and 1 of 21 with the 80 mg dose. No differences in SAEs (13%, 17%, 14%) or death (8.3%, 4.2%, 4.8%) were observed among the 3 groups. Three adverse events (chills, muscle rigidity, hepatotoxicity) were judged to be related to otaplimastat. INTERPRETATION: Intravenous otaplimastat adjunctive therapy in patients receiving rtPA is feasible and generally safe. The functional efficacy of otaplimastat needs to be investigated with further large trials. ANN NEUROL 2020;87:233-245.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Kim JS, Lee KB, Park JH, et al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2019. PMID: 31721277. doi:10.1002/ana.25644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。